Peerview Oncology & Hematology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/NMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chimeric antigen receptor T-cell (CAR T) therapy, a validated novel therapeutic strategy in leukemic and lymphoid malignancies, continues to provide new hope for many patients, including those with multiple myeloma, with limited treatment options. Multiple new indications for CAR T-cell therapies have been approved by the FDA already this year, and new research may expand treatment options for patients with heavily pretreated disease or those receiving earlier lines of treatment. With these new therapeutic opportunities, questions arise regarding best practices for using CAR T-cell therapy in the clinic. Check out PeerView’s “Seminars and Tumor Board” program featuring the latest research and expert guidance on the role of CAR T-cell therapy in modern hematologic cancer care. Gain a thorough understanding of the latest efficacy and safety data on these therapies, and learn how t

Go online to PeerView.com/NDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with severe asthma, uncontrolled symptoms, and exacerbations are at risk of losing lung function over time. Despite the availability of numerous treatments, many patients with severe asthma remain uncontrolled. Evolving insights into the pathophysiology of severe asthma have led to the development of biologic therapies that target epithelial alarmins, and their use is not restricted by phenotype/endotype or biomarkers. In this activity, based on a recent live web broadcast, our experts will review the latest clinical data, including key insights from medical congresses up to and including ATS 2022, with respect to novel and emerging therapies and other factors that impact the selection of treatment for patients with severe asthma who continue to have uncontrolled disease despite treatment. You will achieve greater insight into the most up-to-date evidence on the pathoph

Go online to PeerView.com/ZBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease. Upon completion of this activity, participa

Go online to PeerView.com/VDU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and many ongoing trials and innovative approaches are anticipated to further escalate progress in this challenging subtype of lung cancer. These developments have also provided new hope to patients with SCLC, which makes it important to ensure that all patients have access to these therapies and can have the opportunity to benefit from them, as well as being encouraged to consider clinical trial participation. This activity, bas

Go online to PeerView.com/JJJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to make personalized treatment choices with the potent suite of targeted agents, including BTK and BCL-2 inhibitors, that have become standards of care in chronic lymphocytic leukemia (CLL)? In collaboration with the CLL Society, this PeerView MasterClass & Case Forum, based on a live event at the ASCO Annual Meeting, will give learners foundational insights on the evidence that supports the use of personalized therapy with modern targeted platforms. Watch the expert panel present a series of highly practical case discussions that include guidance on: the evidence-based selection of treatment strategies for treatment-naïve and relapsed CLL; therapeutic planning based on safety considerations; and the integration of novel combinatorial and cellular therapy strategies. Don't miss this expert-led program and receive CME/MOC credit! Upon completion of this activity

Go online to PeerView.com/DPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and validation of the Bruton tyrosine kinase (BTK) inhibitor agent class in chronic lymphocytic leukemia (CLL) has informed the modern, more personalized approach to patient management—are you prepared to challenge your skills and see how the experts navigate this changed clinical landscape? Find out by viewing this Clinical Consults educational activity recorded at the annual European hematology meeting in Vienna; throughout experts will explore the evidence-based use of BTK inhibitors in these different CLL settings. Tune in to see case-based guidance on modern, customized therapy selection based on prognostic factors, safety and selectivity differences between available agents, and treatment settings in the context of EU and US practice. Upon completion of this activity, participants should be better able to: Describe current evidence from pivotal clinical tria

Go online to PeerView.com/DGJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on recent evidence on acute lymphoblastic leukemia (ALL) emerging from major scientific congresses? In this activity, an ALL specialist explores recent evidence presented at the 2022 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings on developments in various treatment modalities for ALL. Watch this video to hear about the latest evidence and practical applications in asparaginase use in chemotherapy protocols, including important dosing and safety data on recombinant Erwinia; get updated on longer-term outcomes with CAR-T therapy in adult and pediatric patients and hear practical considerations when using CAR-T options; and learn about emerging chemo-sparing TKI plus bispecific combinations in Ph-positive ALL. Upon completion of this activity, participants should be better able to: Summarize new evidence on

Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents wi

Go online to PeerView.com/SDX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The arrival of immunotherapy in basal cell carcinoma (BCC) increases the potential for successful treatment outcomes—are you prepared to address several practical questions related to selection and sequencing of immunotherapy, safety management, and patient monitoring? In this activity, based on a recent PeerView Live Seminars & Tumor Board educational event held at the 2022 American Society of Clinical Oncology Annual Meeting, our expert panel links the evidence supporting the use of immunotherapy in locally advanced and metastatic BCC with case-based teaching designed to mimic the collaborative aspects of real-world, multidisciplinary tumor boards, ultimately illustrating how checkpoint inhibitors can be integrated into the care of patients with BCC. Leverage the power of immunotherapy to improve clinical outcomes for your patients with advanced BCC! Upon completion of thi

Go online to PeerView.com/NUC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to keep up with changes to the treatment landscape of hepatocellular carcinoma (HCC) as the choice of regimens for patients with intermediate- to advanced-stage disease continues to expand and innovative locoregional and multimodal strategies move closer to entering mainstream clinical practice? With several available treatment modalities, HCC requires a multidisciplinary approach that is based on both disease stage and a variety of patient- and treatment-specific factors. Participate in this PeerView activity for an in-depth examination of how interventional radiologists can collaborate with the HCC management team to offer the best possible care for their patients! Upon completion of this activity, participants should be better able to: Evaluate the current and emerging therapeutic roles of and key clinical evidence on novel systemic therapy options, including

Go online to PeerView.com/HVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What is your sense of the “next steps” with practice-changing immunotherapy options for head and neck cancer (HNC)? Future advances will likely be driven by longer-term evidence in recurrent/metastatic disease, the use of immunotherapy in conjunction with surgery and radiotherapy, the potential of novel combinatorial regimens, and the emergence of newer PD-1–targeting therapies or innovative immune-based treatments. In this “Clinical Consult” activity, based on a live symposium held at the 2022 ASCO Annual Meeting and developed in collaboration with the Head and Neck Cancer Alliance (HNCA), a panel of experts will use case-based conversations to illustrate the present and future of immunotherapy across lines of care in HNC and provide guidance on the next wave of innovation emerging from clinical trials. Upon completion of this activity, participants should be better able to: Su

Go online to PeerView.com/RGK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced and metastatic NSCLC without actionable genomic alterations, with a number of single-agent and combinatorial options available for clinical use. In light of demonstrably improved outcomes in the metastatic setting, ICIs are transitioning to earlier disease settings as part of perioperative neoadjuvant and/or adjuvant treatment strategies, which will likely result in reduced recurrence rates and more patients achieving cure. The number of available ICIs is expected to grow, as many new agents and combinations are in the final stages of testing, and novel checkpoints such as TIGIT and LAG-3 are showing promise in clinical trials. Consequently, predictive biomarker testing to refine treatment selection is paramount, and there is

Go online to PeerView.com/KVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. CDK4 and 6 inhibitors and endocrine therapy have significantly improved outcomes in ER+/HER2- advanced breast cancer, and recently, the first CDK4 and 6 inhibitor was approved in combination with endocrine therapy in the adjuvant setting for patients with HR+/HER2-, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score of ≥20%. However, pretreated ER+/HER2- breast cancer remains a challenging area with limited treatment options. A number of novel ER-targeting therapies are being investigated in this setting and are showing great promise, including oral selective estrogen receptor degraders (SERDs), selective estrogen receptor modifiers (SERMs), SERD/SERM hybrids, selective estrogen receptor covalent antagonists (SERCAs), and proteolysis-targeting chimeras (PROTACs). This activity, based on a PeerView Live Seminars & Practicum educational web broadca

Go online to PeerView.com/NVX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid validation of novel cytotoxic, targeted, and epigenetic treatment approaches in acute myeloid leukemia (AML) has quickly augmented—and in some cases, eclipsed—long-standing options centered around standard cytarabine-based regimens. These developments have afforded clinicians the opportunity to develop truly personalized treatment protocols designed to overcome therapeutic challenges in different AML populations. This activity will prepare learners for the increasingly personalized management of AML through a series of case-based, expert-led conversations on modern AML care. The panelists discuss topics such as the changing nature of upfront therapy, the challenges of selecting postremission maintenance, and new developments in selecting evidence-based therapy for R/R AML. Learn how to skillfully deploy novel therapeutics in AML—watch today! Upon completion of this act

Go online to PeerView.com/YEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In collaboration with HealthTree Foundation, this “Seminars and Tumor Board” program makes new developments in multiple myeloma (MM) care comprehensible by focusing on how the “myelennial” tool kit can be leveraged for different patient populations and in different treatment settings. Using a series of case-based sessions, our expert panelists provide instruction on the use of next-generation triplets and quadruplets, maintenance strategies, and effective therapeutics in early relapse and treatment-refractory disease. Link cutting-edge evidence in MM to clinical decisions in your own practice—watch today! Upon completion of this activity, participants should be better able to: Cite current practice recommendations and clinical evidence surrounding the efficacy of novel proteasome inhibitor and IMiD options, novel antibody platforms, targeted agents, and cellular therapy across M

Go online to PeerView.com/TJS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid expansion of the renal cell carcinoma (RCC) therapeutic landscape has opened doors for clinical practice advancements for medical and urologic oncologists. The long-term data supporting the efficacy of dual checkpoint blockade, together with further follow-up reported for established immunotherapy-TKI partners, as well as new efficacious combinations, has increased the number of treatment choices in the frontline setting of advanced RCC as well. Designed to bridge the gap between theory and practice, this CME/MOC-certified educational activity, in partnership with KCCure, features expert guidance on how oncologists can integrate novel therapeutics, including immunotherapy, targeted therapy, and promising combination strategies, into the care of patients with RCC in a variety of settings. Upon completion of this activity, participants should be better able to: Assess th

Go online to PeerView.com/NGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for new standards of care in HCC management—and the implications for optimized, sequential treatment? Find out by viewing this educational activity, based on a recent PeerView Live event, where our experts will demonstrate how to develop a highly personalized management model in HCC that exploits potent new immunotherapy combinations, modern TKI therapy, and newer treatment modalities. Throughout, our experts will provide “Tumor Board”-style illustrations of how to address the needs of a given patient, implement appropriate therapeutic sequencing, and embrace the increasingly important role of multidisciplinary care across the disease continuum. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of new and novel systemic therapy options and combinations for patients with advanced HCC, I

Go online to PeerView.com/EBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The discovery of immune checkpoints that regulate immune responses transformed cancer care, and the impact that the new class of immune checkpoint inhibitors (ICIs) has had in oncology cannot be understated. A proportion of patients achieve remarkable and durable responses and improved overall survival with use of the current ICIs. However, there are a number of limitations associated with the current immunotherapies, patient outcomes are still suboptimal, and new options are needed to maximize the potential of cancer immunotherapy as the fourth treatment pillar in oncology. New rational combinations leveraging synergies between old and new checkpoints have emerged, with inhibitory targeting of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine–based inhibitory motif domains (TIGIT) along with the PD-L1/PD-1 pathway as one potential strategy under extensive in

Go online to PeerView.com/KQX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The use of asparaginase, including E coli- and Erwinia-derived compounds, remains an important component of pediatric acute lymphoblastic leukemia (ALL) care, and its use has consistently improved survival outcomes—are you up to the challenge of developing modern regimens that ensure appropriate exposure to asparaginase? In this PeerView CME activity, based on a live “Clinical Consults” symposium at the 2022 ASPHO conference, Drs. Stuart S. Winter and Reuven Schore address the challenges of clinical decision-making with asparaginase compounds as part of pediatric ALL therapy, focusing on topics such as the management of E coli-derived asparaginase hypersensitivity or silent inactivation, preventing discontinuation/truncation, and the integration of novel Erwinia formulations when E coli-derived asparaginase discontinuation occurs. Tune in to learn how to adapt your practice to r

Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments. Upon completion of this activity, participants should be better able to: